Annual report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2016
DOI:
https://doi.org/10.33321/cdi.2019.43.3Abstract
As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a total of 4,247 human influenza positive samples during 2016. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties and also propagated in qualified cells and hens eggs for potential seasonal influenza vaccine virus candidates. In 2016, influenza A(H3) viruses predominated over influenza A(H1)pdm09 and B viruses, accounting for a total of 51% of all viruses analysed. The vast majority of A(H1)pdm09, A(H3) and influenza B viruses analysed at the Centre were found to be antigenically similar to the respective WHO recommended vaccine strains for the Southern Hemisphere in 2016. However, phylogenetic analysis of a selection of viruses indicated that the majority of circulating A(H3) viruses had undergone some genetic drift relative to the WHO recommended strain for 2016. Of more than 3,000 samples tested for resistance to the neuraminidase inhibitors oseltamivir and zanamivir, six A(H1)pdm09 viruses and two B/Victoria lineage viruses showed highly reduced inhibition to oseltamivir.
Downloads
References
Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol. 2008 Jul;46(7):2189-94. PubMed PMID: 18480230. Pubmed Central PMCID: 2446904. Epub 2008/05/16. eng.
Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972 Dec;70(4):767-77. PubMed PMID: 4509641. Pubmed Central PMCID: 2130285. Epub 1972/12/01. eng.
Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? Journal of virology. 2010 Jul;84(13):6769-81. PubMed PMID: 20410266. Pubmed Central PMCID: 2903250.
Hurt AC, Okomo-Adhiambo M, Gubareva LV. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods in molecular biology. 2012;865:115-25. PubMed PMID: 22528156.
Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antiviral Res. 2016 Aug;132:178-85. PubMed PMID: 27265623. Pubmed Central PMCID: Pmc5357725. Epub 2016/06/07.eng.
WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: World Health Organization; 2011.
Sullivan SG, Chow MK, Barr IG, Kelso A. Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2014. Communicable diseases intelligence quarterly report. 2015;39(4):E602-11. PubMed PMID: 26779736. Epub 2016/01/19.eng.
Leung VK, Spirason N, Lau H, Buettner I, Leang SK, Chow MK. Influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza annual report, 2015. Communicable diseases intelligence quarterly report. 2017 June 2017;41(2):E150-E60.
Australian Government Department of Health. National Notifiable Diseases Surveillance System Canberra: Australian Government Department of Health; 2016 [cited 2017 18 April 2017]. Available from: http://www9.health.gov.au/cda/source/cda-index.cfm.
Health AGDo. Australian Influenza Surveillance Report No 11 - 15 September to 28 October 2016. 2016.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the united states. JAMA. 2004;292(11):1333-40.
Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, et al. WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine. 2014 Aug 20;32(37):4713-25. PubMed PMID: 24582632. Epub 2014/03/04.eng.
Kissling E, Rondy M. Early 2016/17 vaccine effectiveness estimates against influenza A (H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Eurosurveillance. 2017;22(7).
Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2017 Feb 09;22(6). PubMed PMID: 28205503. Pubmed Central PMCID: Pmc5316907. Epub 2017/02/17.eng.
Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, et al. Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. MMWR Morbidity and mortality weekly report. 2017 Feb 17;66(6):167-71. PubMed PMID: 28207689. Epub 2017/02/17.eng.
Published
How to Cite
License
Copyright (c) 2019 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
